Colinz Laboratories Limited , a pharmaceutical formulations manufacturer, has announced its unaudited financial results for the second quarter and half-year ended September 30, 2025. The company's performance shows mixed results with a decrease in revenue but an increase in profitability.

Financial Highlights

Quarterly Performance

Colinz Laboratories experienced a decline in revenue from operations for the quarter ended September 30, 2025. The company reported revenue of ₹138.80 lakhs, down from ₹156.61 lakhs in the previous quarter. Despite the revenue dip, the company managed to improve its bottom line, with net profit increasing to ₹14.05 lakhs from ₹11.92 lakhs in the prior quarter.

Half-Year Results

For the half-year period, Colinz Laboratories posted revenue from operations of ₹295.41 lakhs. The net profit for the same period stood at ₹25.97 lakhs, indicating a positive trend in the company's profitability.

Balance Sheet Strength

The company's financial position appears to be stable. As of September 30, 2025, Colinz Laboratories reported total assets of ₹1,212.62 lakhs, showing an increase from ₹1,181.74 lakhs recorded in March 2025. Notably, the company maintains a strong liquidity position with cash and cash equivalents of ₹742.18 lakhs.

Corporate Governance

The financial results were reviewed by the audit committee and subsequently approved by the board of directors. Vora Associates, the statutory auditors of the company, issued an unqualified review report on the financial statements, providing assurance on the accuracy of the reported figures.

Conclusion

While Colinz Laboratories faced a quarter-on-quarter revenue decline, the improvement in net profit suggests effective cost management. The company's strong cash position and growing asset base indicate financial stability, which could support future growth initiatives in the pharmaceutical sector.

Colinz Laboratories Ltd has announced plans to sell two key assets valued at a minimum of Rs 6.00 crores, subject to shareholder approval through a postal ballot. The Board of Directors approved the proposal on October 14, 2025, to dispose of a pharmaceutical manufacturing factory in Sinnar, Nashik, and office premises in Mumbai.

Asset Details and Rationale

The assets slated for sale include:

1. Pharmaceutical Manufacturing Factory:

   • Location: Plot No 60, STICE, Sinnar-Shirdi Road, Sinnar, Nashik-422112
   • Minimum Valuation: Rs 3.00 crores
   • Rationale for Sale:
     • High costs associated with modifying the factory to comply with new WHO norms
     • Deteriorating infrastructure (constructed between 1995-1998)
     • Need for extensive modifications, new machinery, and additional manpower

2. Office Premises:

   • Location: A-101, A-102, A-103 Pratik Estate, Mulund Link Road, Bhandup West, Mumbai-400078
   • Total Area: 1088 sq feet (across three units)
   • Minimum Valuation: Rs 3.00 crores
   • Rationale for Sale:
     • 25-year-old premises lacking basic facilities like elevators and adequate parking
     • Redevelopment constraints due to nearby electric tower installations

Shareholder Approval Process

The company is seeking shareholder approval through a postal ballot with the following key dates:

• E-voting Period: October 15 to November 14, 2025
• Cut-off Date for Shareholder Eligibility: October 7, 2025

Future Plans

Colinz Laboratories is considering alternative options, including:

• Setting up a new factory in Gujarat
• Acquiring a ready-made facility that complies with revised schedule and WHO norms

The company plans to use the proceeds from the asset sales for these potential investments, aiming to construct a new WHO-compliant facility if funds permit.

Legal and Regulatory Compliance

The proposed sales require shareholder approval as special resolutions under Section 180(1)(a) of the Companies Act, 2013. The transactions are considered material events under SEBI regulations, and necessary stock exchange intimations will be made.

Management Commentary

While no direct quotes were provided, the management's decision appears to be driven by the need to upgrade manufacturing capabilities to meet new regulatory standards and improve operational efficiency. The move also aims to address the limitations of aging infrastructure at both the factory and office locations.

Shareholders will play a crucial role in determining the future direction of Colinz Laboratories through their votes on these proposed asset sales. The outcome of the postal ballot will be a significant factor in shaping the company's strategic plans for modernization and compliance with industry standards.